Facts
- Buckman Company consulted for AcroMed Corporation in seeking FDA clearance to market orthopedic bone screws.
- The screws were Class III medical devices regulated under the Food, Drug, and Cosmetic Act (FDCA), as amended by the Medical Device Amendments of 1976 (MDA).
- AcroMed obtained marketing clearance through the § 510(k) “substantial equivalence” process rather than premarket approval (PMA).
- Plaintiffs alleged Buckman made fraudulent representations to the FDA about the devices’ intended use (describing use in long bones rather than spinal implantation).
- Thousands of plaintiffs claiming injuries from spinal implantation asserted state-law “fraud-on-the-FDA” tort claims, alleging they would not have been injured but for the fraud that induced FDA clearance.
- The district court dismissed the fraud-on-the-FDA claims as preempted; the Third Circuit reversed.
Issues
- Whether the FDCA/MDA impliedly preempts state-law tort claims whose theory of liability is that a defendant defrauded the FDA to obtain medical device clearance.
Decision
- The Supreme Court reversed the Third Circuit and held the state-law fraud-on-the-FDA claims impliedly preempted.
- The Court reasoned that the FDA–regulated entity relationship is exclusively federal, so the usual presumption against preemption applicable to traditional state health and safety regulation did not control.
- State tort litigation over alleged fraud on the FDA would conflict with the federal scheme by interfering with the FDA’s judgment about what information it needs and how to balance regulatory objectives.
- Allowing such claims would risk overdeterrence (e.g., excessive or strategic disclosures) and chill communications the FDA considers adequate.
- The FDCA vests enforcement authority in the federal government and does not provide a private right to enforce FDCA disclosure duties; state fraud-on-the-FDA suits would function as private enforcement inconsistent with that structure.
- A separate concurrence agreed with reversal but would resolve the case on narrower grounds.
Legal Principles
- State-law claims premised on alleged fraud on the FDA in obtaining medical device clearance or approval are impliedly preempted by the FDCA/MDA because they conflict with the federal regulatory scheme.
- Duties to make particular disclosures to the FDA arise from federal law; using state tort law to police those duties intrudes into federal control over agency communications.
- The FDCA’s enforcement design, which assigns policing of fraud against the FDA to the federal government, bars state-law theories that effectively create private enforcement of FDCA requirements.
- The decision does not, by itself, preempt traditional state tort claims (e.g., design defect or failure to warn) that rest on independent state duties rather than on fraud directed at the FDA.
Conclusion
The Court held that the FDCA/MDA impliedly preempts state tort claims alleging that a defendant’s misrepresentations to the FDA caused injury by inducing device clearance, because such claims conflict with the FDA-centered federal enforcement and regulatory framework.